. Author manuscript; available in PMC: 2020 May 15.

Published before final editing as: J Matern Fetal Neonatal Med. 2018 Nov 15:1–7. doi: 10.1080/14767058.2018.1540582

Table 1:

Model Inputs

Outcome	Probability^a		Cost (2017$)^b	Utility^c	QALY^d
	With BMZ^h	Without BMZ
Overall RDS^e	0.055²	0.064	----	----	----
Overall TTN^f	0.067	0.099	----	----	----
Overall Hypoglycemia^g	0.24	0.15	----	----	----
RDS without hypoglycemia^e	0.042	0.054	35,813	0.87	0.018
TTN without hypoglycemia ^f	0.051	0.084	9,292	0.93	0.019
Hypoglycemia without respiratory morbidity^g	0.21	0.13	9,733	0.94	0.019
RDS and hypoglycemia	0.013	0.0096	45,545	0.87	0.018
TTN and hypoglycemia	0.016	0.015	19,025	0.90	0.018
No adverse outcome	0.67	0.71	2,240	1	0.021

^a:

source ²

^b:

source ¹⁰. For patients who received BMZ $169 was added to the cost to account for the cost of the medication.

^c:

source ¹²

^d:

quality-adjusted life-year source

^e:

respiratory distress syndrome

^f:

transient tachypnea of the newborn

^g:

defined as blood glucose measurement of <40 mg/dL at any time during the initial hospitalization after birth

^h:

betamethasone